Shares of Quotient Limited (NASDAQ:QTNT) were up 6.7% during trading on Wednesday . The company traded as high as $5.14 and last traded at $4.51. Approximately 326,352 shares were traded during trading, an increase of 39% from the average daily volume of 234,022 shares. The stock had previously closed at $4.84.

A number of analysts have commented on QTNT shares. Zacks Investment Research raised shares of Quotient Limited from a “sell” rating to a “hold” rating in a research report on Wednesday, May 17th. ValuEngine raised shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th. Finally, BTIG Research reaffirmed a “buy” rating and set a $12.00 price target on shares of Quotient Limited in a research report on Thursday, August 31st.

The stock’s market cap is $62.54 million. The company’s 50 day moving average price is $4.37 and its 200 day moving average price is $6.25.

Quotient Limited (NASDAQ:QTNT) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.55). Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. The firm had revenue of $6.83 million for the quarter, compared to analysts’ expectations of $5.70 million. Equities analysts expect that Quotient Limited will post ($2.01) EPS for the current fiscal year.

In other Quotient Limited news, insider D J. Paul E. Cowan sold 20,580 shares of the business’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $6.29, for a total value of $129,448.20. Following the transaction, the insider now owns 26,666 shares in the company, valued at $167,729.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider D J. Paul E. Cowan sold 45,032 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $6.57, for a total transaction of $295,860.24. Following the completion of the transaction, the insider now owns 26,666 shares in the company, valued at approximately $175,195.62. The disclosure for this sale can be found here. Insiders sold 265,612 shares of company stock worth $1,443,079 in the last 90 days. Corporate insiders own 29.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in QTNT. New York State Common Retirement Fund purchased a new position in shares of Quotient Limited in the second quarter valued at about $101,000. Goldman Sachs Group Inc. purchased a new position in shares of Quotient Limited during the second quarter valued at about $104,000. Nationwide Fund Advisors purchased a new position in shares of Quotient Limited during the second quarter valued at about $111,000. The Manufacturers Life Insurance Company purchased a new position in shares of Quotient Limited during the second quarter valued at about $177,000. Finally, Rhumbline Advisers purchased a new position in shares of Quotient Limited during the second quarter valued at about $201,000. Hedge funds and other institutional investors own 57.68% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/13/quotient-limited-qtnt-trading-6-7-higher.html.

About Quotient Limited

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Receive News & Stock Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related stocks with our FREE daily email newsletter.